| SEC | Form | 4 |
|-----|------|---|
|     |      |   |

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SION OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 10b5-1(c). See Instruction 10.  |   |  |  |  |  |
|---|---|--|--|--|--|
| 1. Name and Address of Reporting Person <sup>*</sup><br>Andraczke Andrzej | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br><u>CNS Pharmaceuticals, Inc.</u> [ CNSP ] | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>X Director 10% Owner   |  |  |  |
| (Last) (First) (Middle)   | 3. Date of Earliest Transaction (Month/Day/Year)<br>09/21/2023                                  | Officer (give title Other (specify below) below)   |  |  |  |
| C/O CNS PHARMACEUTICALS, INC.<br>100 WEST LOOP SOUTH, SUITE 900           | 4. If Amendment, Date of Original Filed (Month/Day/Year)<br>09/25/2023                          | <ol> <li>Individual or Joint/Group Filing (Check Applicable Line)</li> <li>X Form filed by One Reporting Person</li> <li>Form filed by More than One Reporting Person</li> </ol> |  |  |  |
| (Street)<br>HOUSTON TX 77027  |   |  |  |  |  |
| (City) (State) (Zip)  |   |  |  |  |  |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (I | , | Date | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | Transaction<br>Code (Instr. |   | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and 5) |               |       | Following Reported                 | (Instr. 4) | Beneficial<br>Ownership |
|-------------------------|---|------|---|-----------------------------|---|--|---------------|-------|------------------------------------|------------|-------------------------|
|                         |   |      |   | Code                        | v | Amount   | (A) or<br>(D) | Price | Transaction(s)<br>(Instr. 3 and 4) |            | (Instr. 4)              |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security (Instr.<br>3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transac<br>Code (In<br>8) |   | 5. Number of<br>Derivative<br>Securities<br>Acquired (A) or<br>Disposed of<br>(D) (Instr. 3, 4<br>and 5) |     | (Month/Day/Year)    |                    | 7. Title and Amount of<br>Securities Underlying<br>Derivative Security (Instr.<br>3 and 4) |                                     | Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported | Ownership<br>Form:<br>Direct (D) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|--|---|---------------------------------|---|--|-----|---------------------|--------------------|--|-------------------------------------|--------------------------------------|--|----------------------------------|--|
|   |   |  |   | Code                            | v | (A)  | (D) | Date<br>Exercisable | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of Shares |                                      | Transaction(s)<br>(Instr. 4)   |                                  |  |
| Option to<br>purchase<br>common stock               | \$1.09  | 09/21/2023                                 |   | A                               |   | 39,475   |     | (1)                 | 09/22/2033         | Common<br>Stock  | 39,475                              | (2)                                  | 45,428   | D                                |  |

## Explanation of Responses:

1. The stock options set forth in this table vest on the earlier of the one-year anniversary of the date of issuance or the date of the 2024 annual meeting, subject to the grantee's continued service to the Company on the vesting date. 2. The stock options were issued in connection with the reporting person's Board of Director services to the Company.

## Remarks:

This amendment is being filed solely to correct the number of shares of common stock underlying the reported option, and total number of derivative securities owned following the reported transaction.

/s/ Christopher Downs, Attorneyin-fact <u>10/12/2023</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.